Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Barreiro

Showing results (51-60 of 220) with videos related to

Pageof 22
Sort By:
The Journal of Antimicrobial Chemotherapy|December 24, 2011
Pharmacogenetics of hepatitis CVincent Soriano, Eva Poveda, Eugenia Vispo, et al.
Expert Opinion on Drug Safety|June 5, 2013
Antiretroviral drug-related toxicities - clinical spectrum, prevention, and managementJose V Fernandez-Montero, Eugenia Eugenia, Pablo Barreiro, et al.
Infectious Disease Clinics of North America|October 23, 2012
Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral eraVincent Soriano, Pablo Labarga, Eugenia Vispo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 24, 2012
Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the LiverPablo Barreiro, Eugenia Vispo, Eva Poveda, et al.
AIDS (London, England)|June 7, 2013
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patientsEugenia Vispo, José Vicente Fernández-Montero, Pablo Labarga, et al.
Current HIV/AIDS Reports|July 9, 2013
Update on HIV/HCV coinfectionVincent Soriano, Eugenia Vispo, Jose Vicente Fernandez-Montero, et al.
AIDS Reviews|March 23, 2023
Viral hepatitis in persons living with HIV in the post-COVID eraVicente Soriano, Víctor Moreno-Torres, Carmen de Mendoza, et al.
AIDS Reviews|May 16, 2020
COVID-19 Comes 40 Years After AIDS - Any Lesson?Vicente Soriano, Pablo Barreiro, José Manuel Ramos, et al.
Expert Opinion on Pharmacotherapy|April 24, 2014
Dolutegravir, abacavir and lamivudine as HIV therapyJose Vicente Fernandez-Montero, Pablo Barreiro, Pablo Labarga, et al.
Journal of Clinical Microbiology|February 10, 2004
Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutationsCarmen de Mendoza, Ellen Paxinos, Pablo Barreiro, et al.
Pageof 22

Showing results (51-60 of 220) with videos related to

Sort By:
Pageof 22
The Journal of Antimicrobial Chemotherapy|December 24, 2011
Pharmacogenetics of hepatitis CVincent Soriano, Eva Poveda, Eugenia Vispo, et al.
Expert Opinion on Drug Safety|June 5, 2013
Antiretroviral drug-related toxicities - clinical spectrum, prevention, and managementJose V Fernandez-Montero, Eugenia Eugenia, Pablo Barreiro, et al.
Infectious Disease Clinics of North America|October 23, 2012
Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral eraVincent Soriano, Pablo Labarga, Eugenia Vispo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 24, 2012
Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the LiverPablo Barreiro, Eugenia Vispo, Eva Poveda, et al.
AIDS (London, England)|June 7, 2013
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patientsEugenia Vispo, José Vicente Fernández-Montero, Pablo Labarga, et al.
Current HIV/AIDS Reports|July 9, 2013
Update on HIV/HCV coinfectionVincent Soriano, Eugenia Vispo, Jose Vicente Fernandez-Montero, et al.
AIDS Reviews|March 23, 2023
Viral hepatitis in persons living with HIV in the post-COVID eraVicente Soriano, Víctor Moreno-Torres, Carmen de Mendoza, et al.
AIDS Reviews|May 16, 2020
COVID-19 Comes 40 Years After AIDS - Any Lesson?Vicente Soriano, Pablo Barreiro, José Manuel Ramos, et al.
Expert Opinion on Pharmacotherapy|April 24, 2014
Dolutegravir, abacavir and lamivudine as HIV therapyJose Vicente Fernandez-Montero, Pablo Barreiro, Pablo Labarga, et al.
Journal of Clinical Microbiology|February 10, 2004
Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutationsCarmen de Mendoza, Ellen Paxinos, Pablo Barreiro, et al.
Pageof 22